EBS Relative Valuation
EBS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EBS is overvalued; if below, it's undervalued.
Historical Valuation
Emergent BioSolutions Inc (EBS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 14.08. The fair price of Emergent BioSolutions Inc (EBS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：12.05
Fair
4.06
PE
1Y
3Y
5Y
Trailing
Forward
7.50
EV/EBITDA
Emergent BioSolutions Inc. (EBS) has a current EV/EBITDA of 7.50. The 5-year average EV/EBITDA is -669.46. The thresholds are as follows: Strongly Undervalued below -6784.75, Undervalued between -6784.75 and -3727.11, Fairly Valued between 2388.18 and -3727.11, Overvalued between 2388.18 and 5445.83, and Strongly Overvalued above 5445.83. The current Forward EV/EBITDA of 7.50 falls within the Historic Trend Line -Fairly Valued range.
4.14
EV/EBIT
Emergent BioSolutions Inc. (EBS) has a current EV/EBIT of 4.14. The 5-year average EV/EBIT is -6.08. The thresholds are as follows: Strongly Undervalued below -78.60, Undervalued between -78.60 and -42.34, Fairly Valued between 30.18 and -42.34, Overvalued between 30.18 and 66.44, and Strongly Overvalued above 66.44. The current Forward EV/EBIT of 4.14 falls within the Historic Trend Line -Fairly Valued range.
0.56
PS
Emergent BioSolutions Inc. (EBS) has a current PS of 0.56. The 5-year average PS is 0.93. The thresholds are as follows: Strongly Undervalued below -0.74, Undervalued between -0.74 and 0.10, Fairly Valued between 1.77 and 0.10, Overvalued between 1.77 and 2.60, and Strongly Overvalued above 2.60. The current Forward PS of 0.56 falls within the Historic Trend Line -Fairly Valued range.
4.72
P/OCF
Emergent BioSolutions Inc. (EBS) has a current P/OCF of 4.72. The 5-year average P/OCF is 6.02. The thresholds are as follows: Strongly Undervalued below -15.41, Undervalued between -15.41 and -4.69, Fairly Valued between 16.74 and -4.69, Overvalued between 16.74 and 27.45, and Strongly Overvalued above 27.45. The current Forward P/OCF of 4.72 falls within the Historic Trend Line -Fairly Valued range.
3.82
P/FCF
Emergent BioSolutions Inc. (EBS) has a current P/FCF of 3.82. The 5-year average P/FCF is 4.80. The thresholds are as follows: Strongly Undervalued below -22.49, Undervalued between -22.49 and -8.85, Fairly Valued between 18.44 and -8.85, Overvalued between 18.44 and 32.08, and Strongly Overvalued above 32.08. The current Forward P/FCF of 3.82 falls within the Historic Trend Line -Fairly Valued range.
Emergent BioSolutions Inc (EBS) has a current Price-to-Book (P/B) ratio of 1.09. Compared to its 3-year average P/B ratio of 0.60 , the current P/B ratio is approximately 81.80% higher. Relative to its 5-year average P/B ratio of 1.09, the current P/B ratio is about -0.11% higher. Emergent BioSolutions Inc (EBS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -49.47%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -27.21% , the current FCF yield is about -100.00% lower.
1.09
P/B
Median3y
0.60
Median5y
1.09
0.23
FCF Yield
Median3y
-49.47
Median5y
-27.21
Competitors Valuation Multiple
The average P/S ratio for EBS's competitors is 0.00, providing a benchmark for relative valuation. Emergent BioSolutions Inc Corp (EBS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -21.34%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EBS increased by 26.05% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 4.68 to 8.92.
The secondary factor is the Revenue Growth, contributed -21.34%to the performance.
Overall, the performance of EBS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Emergent BioSolutions Inc (EBS) currently overvalued or undervalued?
What is Emergent BioSolutions Inc (EBS) fair value?
How does EBS's valuation metrics compare to the industry average?
What is the current P/B ratio for Emergent BioSolutions Inc (EBS) as of Dec 05 2025?
What is the current FCF Yield for Emergent BioSolutions Inc (EBS) as of Dec 05 2025?
What is the current Forward P/E ratio for Emergent BioSolutions Inc (EBS) as of Dec 05 2025?